Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Total Current Liabilities (2023 - 2025)

Connect Biopharma Holdings (CNTB) has disclosed Total Current Liabilities for 3 consecutive years, with $13.6 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 60.87% to $13.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.6 million through Dec 2025, up 60.87% year-over-year, with the annual reading at $13.6 million for FY2025, 60.87% up from the prior year.
  • Total Current Liabilities hit $13.6 million in Q4 2025 for Connect Biopharma Holdings, up from $11.4 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $25.3 million in Q4 2023 to a low of $8.5 million in Q4 2024.
  • Historically, Total Current Liabilities has averaged $13.0 million across 3 years, with a median of $11.1 million in 2025.
  • Biggest five-year swings in Total Current Liabilities: crashed 66.54% in 2024 and later surged 60.87% in 2025.
  • Year by year, Total Current Liabilities stood at $25.3 million in 2023, then plummeted by 66.54% to $8.5 million in 2024, then skyrocketed by 60.87% to $13.6 million in 2025.
  • Business Quant data shows Total Current Liabilities for CNTB at $13.6 million in Q4 2025, $11.4 million in Q3 2025, and $10.7 million in Q2 2025.